First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Titel:
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Auteur:
Mark, Michael Froesch, Patrizia Gysel, Katrin Rothschild, Sacha I. Addeo, Alfredo Ackermann, Christoph J. Chiquet, Sabrina Schneider, Martina Ribi, Karin Maranta, Angela Fischer Bastian, Sara von Moos, Roger Joerger, Markus Früh, Martin